J. Goldman & Co’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

J. Goldman & Co’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-940	Closed	-$106K	–	412
2015 Q4	$106K	Sell	940 -33,175	-97%	-$3.65M	0.01%	215
2015 Q3	$4.02M	Buy	+34,115	New	+$4.46M	0.34%	98
2014 Q3	–	Sell	-48,125	Closed	-$853K	–	403
2014 Q2	$853K	Buy	+48,125	New	+$775K	0.06%	191
2013 Q4	–	Sell	-87,500	Closed	-$929K	–	376
2013 Q3	$929K	Buy	+87,500	New	+$765K	0.09%	201

Other funds holding ANAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

J. Goldman & Co's ANAC Position: Q1 2016 in Review

J. Goldman & Co sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q1 2016, closing a stake of 940 shares — an estimated $106K sold.

J. Goldman & Co first reported a position in ANAC in Q3 2013 and held it in 4 quarters. The position peaked at $4.02M in Q3 2015. 199 funds tracked by Wall St. Rank hold ANAC as of Q1 2016.

J. Goldman & Co reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q1 2016 after selling out during the quarter.
J. Goldman & Co sold 940 ANACOR PHARMACEUTICALS INC COM shares in Q1 2016, an estimated $106K.
J. Goldman & Co first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2013 and held it in 4 quarters.
J. Goldman & Co's ANACOR PHARMACEUTICALS INC COM position peaked at $4.02M in Q3 2015.
199 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q1 2016.

Based on J. Goldman & Co's 13F filing for Q1 2016, filed 16 May 2016.